EuroBiotech Report—Sanifit bags €55M, LifeArc backs Kymab, Modag A round, Evotec and Verona

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with investments in three European biotechs. Sanifit led the way, raising a €55.2 million ($62.9 million) series D round that broke the record for private financing of a Spanish biotech. In the U.K., Kymab raised an additional $10 million from LifeArc, with a further $20 million to follow, while over in Germany Modag exited stealth mode with €12 million and plans to trial a neurodegenerative disease drug. Elsewhere, Evotec set the stage for a new crop of startups by again teaming up with the University of Oxford. Verona Pharma named long-time GlaxoSmithKline employee Nina Church as executive director of global clinical development. And more. — Nick Taylor
 
1. Sanifit raises series D, smashing Spanish biotech VC record
 
Sanifit has raised a €55.2 million ($62.9 million) series D round. The financing sets Sanifit up to take its lead drug through phase 3 studies while exploring its potential in other progressive vascular calcification disorders.

2. LifeArc makes $30M Kymab investment to access antibody tech

Kymab is set to receive a $30 million (€26 million) investment from LifeArc in return for access to antibody discovery technologies.  

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

3. Modag raises A round to test disease modifying parkinsonian drug

Modag has exited stealth mode with €12 million ($14 million) in series A funds. The German biotech will use the money to take a treatment for parkinsonian disorders into the clinic.
 
4. Evotec forms Oxford initiative to spawn AI-enabled startups

Evotec has formed a pact to help the University of Oxford’s data-driven drug discovery projects move out of academia. Working with clinical artificial intelligence company Sensyne Health, Evotec will support researchers at the university as they generate data to show the commercial viability of their projects.
 
5. Verona hires ex-GSK researchers for late-phase push in COPD

Verona Pharma has named long-time GlaxoSmithKline employee Nina Church as executive director of global clinical development. The appointment of Church is part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease (COPD).
 
And more articles of note>>    

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.